WO2007133803A3 - Traitement d'infections mycobactériennes - Google Patents

Traitement d'infections mycobactériennes Download PDF

Info

Publication number
WO2007133803A3
WO2007133803A3 PCT/US2007/011722 US2007011722W WO2007133803A3 WO 2007133803 A3 WO2007133803 A3 WO 2007133803A3 US 2007011722 W US2007011722 W US 2007011722W WO 2007133803 A3 WO2007133803 A3 WO 2007133803A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
mycobacterial infections
mediated
mycobacteria
infections caused
Prior art date
Application number
PCT/US2007/011722
Other languages
English (en)
Other versions
WO2007133803A2 (fr
Inventor
Joyce A Sutcliffe
Original Assignee
Rib X Pharmaceuticals Inc
Joyce A Sutcliffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc, Joyce A Sutcliffe filed Critical Rib X Pharmaceuticals Inc
Publication of WO2007133803A2 publication Critical patent/WO2007133803A2/fr
Publication of WO2007133803A3 publication Critical patent/WO2007133803A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des méthodes de traitement, de réduction du risque et de prévention d'infections mycobactériennes, telles que les infections causées ou médiées par Mycobacterium tuberculosis ou les mycobactéries non tuberculeuses, et notamment les infections causées ou médiées par les souches mycobactériennes résistantes ou hautement virulentes, au moyen d'une dose sûre et efficace d'un composé antibiotique.
PCT/US2007/011722 2006-05-15 2007-05-15 Traitement d'infections mycobactériennes WO2007133803A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80077806P 2006-05-15 2006-05-15
US60/800,778 2006-05-15
US89909507P 2007-02-01 2007-02-01
US60/899,095 2007-02-01

Publications (2)

Publication Number Publication Date
WO2007133803A2 WO2007133803A2 (fr) 2007-11-22
WO2007133803A3 true WO2007133803A3 (fr) 2008-01-10

Family

ID=38578556

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011722 WO2007133803A2 (fr) 2006-05-15 2007-05-15 Traitement d'infections mycobactériennes

Country Status (1)

Country Link
WO (1) WO2007133803A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011046905A2 (fr) * 2009-10-13 2011-04-21 Rib-X Pharmaceuticals, Inc. Compositions pharmaceutiques
WO2011139832A2 (fr) * 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Méthode de traitement des infections mycobactériennes
WO2016061772A1 (fr) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Composés nargénicine et leurs utilisations de comme agents antibactériens

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (fr) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Dérivés d'aminométhyloxooxazolidinyl-arylbenzène comme agents antibactériens
WO1993009103A1 (fr) * 1991-11-01 1993-05-13 The Upjohn Company Aryl- et heteroarylphenyloxazolidinones substituees, utilisees comme agents antibacteriens
WO2004029066A2 (fr) * 2002-09-26 2004-04-08 Rib-X Pharmaceuticals, Inc. Composes heterocycliques bifonctionnels et procedes de fabrication et d'utilisation de ces composes
WO2005061468A1 (fr) * 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Composes heterocycliques de biaryle halogenes et methodes de fabrication et d'utilisation
WO2006133397A2 (fr) * 2005-06-08 2006-12-14 Rib-X Pharmaceuticals, Inc. Procede permettant de realiser la synthese de triazoles

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352781A2 (fr) * 1988-07-29 1990-01-31 The Du Pont Merck Pharmaceutical Company Dérivés d'aminométhyloxooxazolidinyl-arylbenzène comme agents antibactériens
WO1993009103A1 (fr) * 1991-11-01 1993-05-13 The Upjohn Company Aryl- et heteroarylphenyloxazolidinones substituees, utilisees comme agents antibacteriens
WO2004029066A2 (fr) * 2002-09-26 2004-04-08 Rib-X Pharmaceuticals, Inc. Composes heterocycliques bifonctionnels et procedes de fabrication et d'utilisation de ces composes
WO2005061468A1 (fr) * 2003-12-17 2005-07-07 Rib-X Pharmaceuticals, Inc. Composes heterocycliques de biaryle halogenes et methodes de fabrication et d'utilisation
WO2006133397A2 (fr) * 2005-06-08 2006-12-14 Rib-X Pharmaceuticals, Inc. Procede permettant de realiser la synthese de triazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WEIDNER-WELLS M A ET AL: "The synthesis and antimicrobial evaluation of a new series of isoxazolinyl oxazolidinones", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 12, 21 June 2004 (2004-06-21), pages 3069 - 3072, XP004841345, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2007133803A2 (fr) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2007106536A3 (fr) Procédés pour induire une réponse immunitaire à la tuberculose
WO2009109532A3 (fr) Utilisation de défensines contre la tuberculose
WO2010090860A3 (fr) Méthodes de traitement d'une infection bactérienne et compositions associées
WO2008115281A3 (fr) Composés de traitement d'infections virales
WO2005077411A3 (fr) Composition et procede pour le traitement de carcinome
WO2009140309A3 (fr) Petites molécules contenant du bore
WO2007097940A3 (fr) Inhibiteurs reca à activité antibiotique, compositions et méthodes d'utilisation
WO2006063176A3 (fr) Inhibition de la formation de biofilm par un bacteriophage
IL186452A0 (en) Methods and means for diagnostics, prevention and treatment of mycobacterium infections and tuberculosis disease
WO2009026166A3 (fr) Composés de flavonol anti-infectieux et leurs procédés d'utilisation
WO2008153610A3 (fr) Utilisation d'antagonistes de il-23 pour le traitement d'une infection
ZA200701629B (en) Gyrase inhibitors and uses thereof
WO2011063263A3 (fr) Procédés de génération de réponse immunitaire à la tuberculose
WO2010015815A3 (fr) Composés pour le traitement d'infections flavivirales
WO2008005651A3 (fr) Dérivés d'acide rhodanine-carboxylique cycliques destinés au traitement et à la prévention de la tuberculose
WO2009085277A3 (fr) Traitement de cicatrices anormales ou excessives
EP2120562A4 (fr) Procédé et compositions utilisés pour traiter les infections à vih
WO2010065735A3 (fr) Procédés et compositions pour traiter p. acnes
EP4143235A4 (fr) Méthodes et compositions pour le traitement d'infections de type choc cytokinique, notamment la covd-19, par inhibition de l'interaction ccr5/ccl5
WO2010032011A8 (fr) Thérapie antifongique
WO2012103295A3 (fr) Inhibiteurs d'arnse à petites molécules et méthodes d'utilisation
IN2012DN01414A (fr)
WO2010134827A9 (fr) Composition générant de l'oxygène à action prolongée utilisée pour traiter les infections microbiennes
WO2007089612A3 (fr) Procédés et compositions pour le traitement et la prévention d'infections bactériennes
WO2008129419A3 (fr) Procédé de détection et/ou d'isolement de mycobactéries

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07794930

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07794930

Country of ref document: EP

Kind code of ref document: A2